All patients
Age < 65y (younger) Age > 65y Asian type cancer location (gastric) cancer location (gastro-esophageal) cancer type (metastatic) ECOG 0 ECOG 1 Gender, female Gender, male previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced mGC or mGEJC, pembrolizumab alone vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.79; 1.12]
KEYNOTE-061 (PDL1 CPS>1), 2018 0.82 [0.66; 1.02]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.91 [0.75; 1.11]
KEYNOTE-062 (P vs C ; CPS>10), 2020 0.69 [0.49; 0.97]
0.88 [0.79 ; 0.97 ] KEYNOTE-061 (all population), 2018, KEYNOTE-061 (PDL1 CPS>1), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020 4 0% 1,675 moderate not evaluable progression or deaths (PFS)detailed results KEYNOTE-061 (all population), 2018 1.49 [1.25; 1.77]
KEYNOTE-061 (PDL1 CPS>1), 2018 1.27 [1.03; 1.57]
KEYNOTE-062 (P vs C ; CPS>1), 2020 1.66 [1.37; 2.01]
KEYNOTE-062 (P vs C ; CPS>10), 2020 1.10 [0.80; 1.52]
1.41 [1.20 ; 1.64 ] KEYNOTE-061 (all population), 2018, KEYNOTE-061 (PDL1 CPS>1), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020 4 52% 1,675 moderate not evaluable objective responses (ORR)detailed results KEYNOTE-061 (all population), 2018 0.88 [0.53; 1.45]
KEYNOTE-061 (PDL1 CPS>1), 2018 1.20 [0.68; 2.09]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.29 [0.19; 0.45]
KEYNOTE-062 (P vs C ; CPS>10), 2020 0.55 [0.29; 1.04]
0.64 [0.33 ; 1.22 ] KEYNOTE-061 (all population), 2018, KEYNOTE-061 (PDL1 CPS>1), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020 4 84% 1,675 moderate not evaluable AE (any grade)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.34 [0.11; 1.06]
0.34 [0.11 ; 1.06 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.09 [0.06; 0.14]
0.09 [0.06 ; 0.14 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.19; 4.80]
0.96 [0.19 ; 4.80 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.19 [0.09; 0.38]
0.19 [0.09 ; 0.38 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable TRAE (any grade)detailed results KEYNOTE-061 (all population), 2018 0.21 [0.14; 0.31]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.11 [0.06; 0.18]
0.15 [0.08 ; 0.30 ] KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020 2 77% 1,068 moderate not evaluable TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.31 [0.21; 0.47]
0.31 [0.21 ; 0.47 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-061 (all population), 2018 2.84 [0.29; 27.42]
2.84 [0.29 ; 27.42 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-061 (all population), 2018 0.55 [0.24; 1.28]
0.55 [0.24 ; 1.28 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.16 [0.01; 3.11]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.30 [0.03 ; 3.29 ] KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020 2 0% 1,068 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.54 [0.21; 1.38]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.10 [0.03; 0.27]
0.23 [0.04 ; 1.25 ] KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020 2 83% 1,068 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.09 [0.01; 0.73]
0.09 [0.01 ; 0.73 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.06; 15.44]
0.96 [0.06 ; 15.44 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.16 [0.01; 3.11]
0.16 [0.01 ; 3.11 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.96 [0.02 ; 48.60 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.16 [0.05; 0.55]
0.56 [0.03 ; 11.52 ] KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020 2 71% 1,068 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
0.94 [0.02 ; 47.47 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.06; 15.08]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.20 [0.06; 0.69]
0.26 [0.08 ; 0.83 ] KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020 2 1% 1,068 moderate not evaluable Dizziness TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
0.48 [0.02 ; 14.35 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.96 [0.02 ; 48.60 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.96 [0.02 ; 48.60 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.49 [0.19; 1.26]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.06 [0.01; 0.50]
0.22 [0.03 ; 1.54 ] KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020 2 68% 1,068 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 7.60 [0.40; 144.43]
7.60 [0.40 ; 144.43 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
0.94 [0.02 ; 47.47 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
3.77 [0.17 ; 84.06 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
KEYNOTE-062 (P vs C ; CPS>1), 2020 1.92 [0.06; 57.64]
1.41 [0.11 ; 18.47 ] KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020 2 0% 1,068 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.47 [0.02; 14.02]
0.47 [0.02 ; 14.02 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
0.48 [0.02 ; 14.35 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.03 [0.00; 0.51]
0.03 [0.00 ; 0.51 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.47 [0.04; 5.19]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.05 [0.01; 0.37]
0.14 [0.02 ; 1.23 ] KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020 2 49% 1,068 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results Out of scale KEYNOTE-061 (all population), 2018 0.02 [0.00; 0.25]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.01 [0.00; 0.08]
0.01 [0.00 ; 0.06 ] KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020 2 0% 1,068 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.06 [0.00; 1.02]
0.06 [0.00 ; 1.02 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.47 [0.02; 14.02]
0.47 [0.02 ; 14.02 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.08 [0.00; 1.38]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.19 [0.02 ; 2.03 ] KEYNOTE-061 (all population), 2018, KEYNOTE-062 (P vs C ; CPS>1), 2020 2 3% 1,068 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
3.77 [0.17 ; 84.06 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.96 [0.02 ; 48.60 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
0.96 [0.02 ; 48.60 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 1.88 [0.06; 56.28]
1.88 [0.06 ; 56.28 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.05 [0.00; 0.89]
0.05 [0.00 ; 0.89 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.08 [0.00; 1.41]
0.08 [0.00 ; 1.41 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.03 [0.00; 0.55]
0.03 [0.00 ; 0.55 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
0.48 [0.02 ; 14.35 ] KEYNOTE-062 (P vs C ; CPS>1), 2020 1 0% 498 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 21:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 273,122,271,262,260,219,184,272,123,187,185,186,304
- treatments: 359,575,577,576,869